Biosimilars in #retina

💡 Biosimilars 101 with Dr. Deepak Sambhara When we talk about biosimilars, we’re diving into biologics—complex medical products that are nearly identical to branded versions but often come at a reduced cost. In the U.S., the Biologics Price Competition and Innovation Act of 2009 paved the way for FDA approval of these meds, with safety and interchangeability as top priorities. In retina care, biosimilars are making waves. But with rapid changes, there’s growing concern among specialists about access to second-gen anti-VEGF treatments. What’s your take on the rise of biosimilars? Share your thoughts below! 👇 #Biosimilars #RetinaCare #Ophthalmology #iDocSocial